Well, things do change in Washington these days on a minute by minute basis and the news cycle continues to amaze even the most skeptical of viewers. Seems like the User Fee Reauthorization is back on track after the House Energy and Commerce Subcommittee rejects the call of the Secretary of HHS to reopen User Fee negotiations. With the exception of a few amendments (some of which are actually quite good for the generic drug industry and were discussed here), it looks like the bill will be moving through Congress basically unscathed.
So wipe your brow and get ready for GDUFA II and another 5-year stint.
